<DOC>
	<DOCNO>NCT02710188</DOCNO>
	<brief_summary>The purpose study find modified release oral tablet formulation drug , safe well tolerate .</brief_summary>
	<brief_title>Relative Bioavailability Study Healthy Subjects Evaluate Pharmacokinetics HTL0009936 After One Dose Prototype Formulation</brief_title>
	<detailed_description>The aim study develop modified release oral tablet formulation maintain plasma concentration within target therapeutic range , safe tolerable .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy male &amp; female Aged 18 65 year Body mass index 18.0 35.0 kg/m2 CYP2D6 ( intermediate extensive metabolizer ) Subjects rest heart rate ( HR ) &gt; 90 bpm , and/or systolic blood pressure ( BP ) &gt; 150 mmHg , and/or diastolic BP &gt; 90 mmHg Subjects QT interval correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 m ( male ) &gt; 470 m ( female ) Personal family history long QT syndrome sudden death Subjects CYP2D6 ( poor ultrarapid metabolizer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>